Identifying a Clear Path Through the Changing Maze of AML Management is organized by Healio, RMEI Medical Education LLC.
Release Date: June 30, 2023
Expiration Date: June 29, 2024
Activity Description
Acute myeloid leukemia (AML), the most common form of leukemia, is characterized by a wide range of cytogenetic and molecular aberrations. These aberrations determine risk classification and, if available, targeted therapy. Recent data has changed the diagnostic threshold for AML, as well as risk classification and data on emerging therapies, by reshaping the future of treatment for newly diagnosed and relapsed/refractory AML. Join Drs. Amer Zeidan and Kendra Sweet as they discuss these and other recent updates in AML.
Educational Objectives
Upon completion of this activity, participants should be better able to:
• Implement molecular testing at diagnosis and relapse to help guide treatment selection in patients with acute myeloid leukemia (AML)?
• Integrate available data on novel therapies into the treatment paradigm of newly diagnosed AML
• Utilize current evidence on novel therapies when treating patients with relapsed/refractory AML
• Manage the unique adverse events associated with the use of novel therapeutics for AML